Subcutaneous Trastuzumab Deruxtecan Phase 1 Trial.
DS8201-801
Phase 1 other active
Quick answer
Subcutaneous Trastuzumab Deruxtecan Phase 1 Trial. for Advanced Solid Tumor is a Phase 1 program (other) at Daiichi Sankyo Europe GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Daiichi Sankyo Europe GmbH
- Indication
- Advanced Solid Tumor
- Phase
- Phase 1
- Modality
- other
- Status
- active